06622.HK
Zhaoke Ophthalmology Limited
HKSE · Healthcare · Biotechnology · CN
HKD 2.50
+0.60%Sep 7, 2026, 02:20 UTC
Zhaoke Ophthalmology announced that its YUVEZZI eye drop reached the primary endpoint in a Phase II clinical study in China for presbyopia patients, and plans to advance to Phase III clinical trials.
Source:Aug 12, 2026, 09:02 UTC
Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.
Source: